SBIR/STTR Research Award
SBIR Phase I: Hydrogel tablets as cost-effective oral dosages for solubility enhancement
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- VERAMORPH LLC
- Proposal award date
- 2020-08-01
- Contract end date
- 2021-07-31
- UEI
- JZD1YYDDCLP5
- Solicitation number
- Not reported
- Topic code
- BM
Research abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to improve the efficacy of drug products through a novel tablet. Current formulation technologies have limited compatibility with the estimated 6
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer
- SBIR Phase II: Design optimization and manufacturing scale-up of oral dosages with environmentally responsive polymers
Research funding history
3 SBIR/STTR records share this UEI (2020–2025). Reported award amounts total $1,624,985. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: National Science Foundation, Department of Health and Human Services